DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Ubicación actual:
> This Story

Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment



Oncology Homepage

New evidence supports mammography screening at age 40 Increasing detection by 19 percent with marginal increase in callbacks, biopsies

IBM and Elekta collab to bridge global cancer care gaps Combining Elekta’s MOSAIQ and IBM’s Watson for Oncology

Vladimir Putin meets with health leaders Discussing the role of proton therapy in Russian health care

New PET imaging agent predicts tumor response to lung cancer drug Could lead to better patient management and outcomes

Study finds most breast cancer patients have better experience with radiation than expected May help put fears to rest

How Mayo Clinic and IBM Watson dramatically improved clinical trial enrollment Mayo sees 80 percent rise in breast cancer trial enrollees

Is proton therapy out of reach for pediatric patients? Initiatives and challenges on the road to improving access to life saving treatment

RaySearch and MD Anderson team up to enhance radiotherapy Aim to raise access to adaptive radiation therapy

Elekta partners with Memorial Sloan Kettering for cancer research on MR-linac Will test MR-linac in treating tumors in nine parts of the body

Pam Papineau Imagin Medical hires director of regulatory affairs

RaySearch will add boron neutron
capture therapy to its portfolio of
treatment modalities through a new
agreement with Neutron Therapeutics

RaySearch enters boron neutron capture therapy field

por John R. Fischer , Staff Reporter
A new alliance has launched RaySearch Laboratories into the field of boron neutron capture therapy (BNCT), a form of radiation treatment that targets cancer at the cellular level.

The Swedish company has partnered with Neutron Therapeutics Inc., a Massachusetts-based company, in a deal that will add BNCT to the RaySearch portfolio of treatment modalities, while applying its technology to a complete single-room solution that utilizes BNCT and is currently being developed by Neutron Therapeutics.

Story Continues Below Advertisement

RaySafe helps you avoid unnecessary radiation

RaySafe solutions are designed to minimize the need for user interaction, bringing unprecedented simplicity & usability to the X-ray room. We're committed to establishing a radiation safety culture wherever technicians & medical staff encounter radiation.

“This partnership is really a response to the fact that BNCT is moving toward broader adoption,” Noah Smick, vice president of business development for Neutron Therapeutics, told HCB News. “There are a number of efforts across the globe aimed at implementing BNCT in hospital environments and generating more definitive clinical data. In our experience, the demand for BNCT today outstrips the supply.”

The use of BNCT is a two-step process that starts out with the injection of a tumor-localizing drug that contains the non-radioactive isotope boron-10. A beam of low-energy neutrons is then applied to the target area with many of the neutrons absorbed by the boron-10. The absorption sets off a reaction in which short-range, high-energy charged particles are emitted to systematically destroy the tumor while minimizing damage to surrounding healthy tissue.

The agreement will extend the functionality of RayStation, which integrates all advanced treatment planning solutions offered by RaySearch into a treatment planning system, to support BNCT planning requirements and add BNCT to the range of treatments offered by RaySearch. These include photon, electron, proton and carbon ion therapy. BNCT users will have access to all advanced functionality features offered by RayStation, including atlas-based segmentation, deformable image registration, and scripting.

The complete single-room solution will include an accelerator-based neutron source, a robotic patient-physician system and a dose engine interfaced to a RayStation treatment planning system (TPS).

Smick says the partnership provides its customers with not only supportive features in the use of BNCT but also ones from an experienced and trustworthy provider.

“RaySearch is widely regarded as the world's leading platform-independent treatment planning system provider,” he said. “The primary benefit to our customers will be the ability to use a TPS for BNCT that they already know and trust. RaySearch has a successful track record of embracing powerful new radiotherapy techniques as they become available. Neutron Therapeutics is pleased that RaySearch has elected to invest in this partnership.”

The first of Neutron Therapeutics’ complete single-room BNCT solutions will be shipped in February to Helsinki University Hospital, with plans for it to be used for clinical purposes starting in 2018.

RaySearch did not respond for comment.

Oncology Homepage

You Must Be Logged In To Post A Comment

Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Certificado recientemente
Ver usuarios certificados recientemente
Recientemente clasificado
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Mantenga el foro de los técnicos
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2018, Inc.